Lost tumor brake found to rewire liver cancer cell power plants

A single molecular switch inside liver cells may help determine whether hepatocellular carcinoma, one of the deadliest and fastest-rising cancers worldwide, gains the self-renewing, energy-hungry properties that make it so hard to treat. That is the central claim of a new study published in the Journal of Translational Medicine, in which researchers in Xi’an, China, identify the adaptor protein LZTR1 as a previously unrecognized guardian of mitochondrial metabolism in liver cancer. When LZTR1 is lost, the team reports, mitochondria are reprogrammed into a state that fuels cancer stemness and tumor growth, while simultaneously exposing a metabolic weakness that could be attacked with existing classes of drugs.

The protein at the heart of the study, leucine-zipper-like transcriptional regulator 1, or LZTR1, has attracted attention in recent years because mutations in its gene are linked to human developmental syndromes and to several cancers. It acts as a cytosolic adaptor for cullin-3 RING E3 ubiquitin ligase complexes, tagging specific target proteins for destruction by the ubiquitin-proteasome system. What remained unclear, the authors note, was whether LZTR1 had any role in controlling mitochondria, the organelles that generate most of a cell’s ATP, and whether such a role mattered for hepatocellular carcinoma, a malignancy in which metabolic reprogramming is a recognized hallmark.

To answer that question, the team combined an unusually broad set of experimental systems. They validated LZTR1’s tumor-suppressive function in vivo using both subcutaneous and orthotopic models derived from hepatocellular carcinoma cells, and they generated mice in which the Lztr1 gene was knocked out specifically in hepatocytes, allowing them to observe what happens when the protein disappears from normal liver tissue rather than from established tumor lines. In parallel, they analyzed tumor specimens collected at Xijing Hospital with ethics committee approval and informed consent, and they mined large clinical datasets, including the Clinical Proteomic Tumor Analysis Consortium, to connect LZTR1 abundance with patient outcomes.

The clinical signal was striking. Low LZTR1 expression correlated with poor prognosis in patients with hepatocellular carcinoma, suggesting that the protein behaves as a genuine tumor suppressor rather than a bystander. Functional experiments reinforced that view: when the researchers removed LZTR1 from liver cancer cells, the cells acquired hallmarks of stemness, the capacity for self-renewal that allows a small subpopulation of tumor cells, often called cancer stem cells, to seed new tumors and survive therapy. Markers of this stem-like state, including aldehyde dehydrogenase activity, rose in the absence of LZTR1, and the cells showed enhanced tumor-initiating behavior in animal models.

Metabolically, the loss of LZTR1 pushed cells toward a distinctive bioenergetic profile. Using Seahorse extracellular flux assays, which measure the oxygen consumption rate of living cells in real time, the team found that LZTR1-deficient cells shifted their metabolism toward oxidative phosphorylation, the mitochondrial ATP-generating pathway, with a particular dependence on respiratory complex I, the first and largest assembly in the electron transport chain. Transcriptomic and proteomic profiling supported the shift, and transmission electron microscopy revealed structural changes in the mitochondria themselves. The reprogramming came at a cost: the cells accumulated reactive oxygen species, experiencing a state of redox stress that accompanies their heightened respiratory activity.

The mechanistic core of the paper explains how a cytosolic adaptor protein manages to govern such a deep mitochondrial program. The target, the researchers discovered, is mitochondrial transcription factor A, or mtTFA, a DNA-binding protein that is imported into mitochondria and controls the transcription and maintenance of mitochondrial DNA. Because mtTFA sits upstream of the entire mitochondrial genome, its abundance sets the ceiling on how much mitochondrial gene expression, and therefore how much respiratory machinery, a cell can build. The team showed, through co-immunoprecipitation, fluorescence resonance energy transfer, proximity ligation assays, super-resolution structured illumination microscopy, and molecular docking studies, that LZTR1 physically binds mtTFA in the cytosol, before the transcription factor reaches the mitochondria.

That physical interaction has a destructive purpose. Ubiquitination assays demonstrated that LZTR1 directs the attachment of K48-linked ubiquitin chains to mtTFA, the molecular signal that condemns a protein to degradation by the proteasome. In other words, LZTR1 acts as a quality-control checkpoint that prevents mtTFA from overaccumulating and driving excessive mitochondrial DNA transcription. When LZTR1 is inactivated, mtTFA piles up, mitochondrial gene expression surges, and the cell’s respiratory machinery expands, producing the complex I-dependent oxidative phosphorylation phenotype the researchers observed. Restoring the checkpoint, or removing mtTFA, reversed the phenotype, establishing mtTFA accumulation as the driver of the LZTR1-deficient state.

The study also reaches one step further upstream, into the emerging field of epitranscriptomics, the chemical modification of RNA. The team found that YTHDF1, a reader protein that binds N6-methyladenosine, or m6A, marks on messenger RNA, positively regulates the translation of LZTR1 in hepatocellular carcinoma in an m6A-dependent manner. This means that the RNA modification landscape of the tumor cell helps set the dosage of the mitochondrial checkpoint, integrating mitochondrial homeostasis into the broader epitranscriptomic network. Disruption anywhere along this axis, from the m6A mark through YTHDF1 to LZTR1 and finally mtTFA, could tilt a liver cell toward the malignant, stem-like, oxidative state.

Two additional findings sharpen the clinical relevance. First, the researchers tested missense mutations of LZTR1 found in liver tumors and in patients with Noonan syndrome, a developmental disorder frequently caused by LZTR1 mutations, and found that most of the variants they examined failed to regulate mtTFA abundance. This suggests that loss of the mtTFA checkpoint may be a common functional consequence of LZTR1 mutation across different disease contexts. Second, and perhaps most therapeutically exciting, the team found that LZTR1-deficient tumors, precisely because of their dependence on complex I-driven oxidative phosphorylation, are more sensitive to complex I inhibition. That vulnerability points toward drugs that target mitochondrial complex I as a rational strategy for the subset of hepatocellular carcinoma patients whose tumors have lost LZTR1, a group that the prognosis data suggest is substantial.

The work, led by Gang Nan, Peng Lin, and Ting Wang as co-first authors, with Jian-Li Jiang, Shi-Jie Wang, and Hong-Yong Cui as corresponding authors at the Fourth Military Medical University, was supported by the National Natural Science Foundation of China and related programs, and was published open access on 31 August 2026. Its broader significance lies in reframing mitochondrial quality control as a cancer-suppressive mechanism: rather than merely responding to metabolic demand, the LZTR1-mtTFA axis actively restrains mitochondrial expansion, and its failure converts a normal regulatory circuit into an engine of tumor progression. If the complex I dependency observed in LZTR1-deficient tumors holds up in clinical testing, a molecular detail of protein turnover in the cytosol could end up defining a new, metabolically targeted treatment strategy for liver cancer.

Subject of Research: LZTR1-mediated mitochondrial quality control and mtTFA regulation in hepatocellular carcinoma progression

Article Title: LZTR1 deficiency reprograms mitochondria via mtTFA stabilization to drive OXPHOS-dependent stemness and progression in HCC

Article References: Nan, G., Lin, P., Wang, T., Fu, X., Tian, R.-F., Jiang, J.-L., Wang, S.-J., & Cui, H.-Y. (2026). LZTR1 deficiency reprograms mitochondria via mtTFA stabilization to drive OXPHOS-dependent stemness and progression in HCC. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08898-1

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08898-1

Keywords: LZTR1, mtTFA, hepatocellular carcinoma, mitochondrial reprogramming, oxidative phosphorylation, complex I, cancer stemness, ubiquitin-proteasome system, m6A modification, YTHDF1, tumor suppressor, metabolic vulnerability